In a nutshell This study investigated the effectiveness and safety outcomes of nimotuzumab (Theraloc) combined with chemoradiotherapy (CRT) for the treatment of patients with locally advanced squamous non-small cell lung cancer (SqNSCLC). The data showed that nimotuzumab plus CRT had similar survival outcomes compared to CRT alone, but with a lower...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This phase 1 trial is examining the safety and effectiveness of a new type of immunotherapy. The treatment involves genetically enhancing patients’ own immune cells to better fight advanced non-small-cell lung cancer (NSCLC) or head and neck cancer. The main outcome to be measured will be the highest safe dose of the treatment. This...
Read MoreIn a nutshell This study compared the effectiveness and safety of nivolumab (Opdivo) and docetaxel (Taxotere) for the treatment of advanced squamous-cell non-small-cell lung cancer (NSCLC). The study concluded that nivolumab is more effective and safer than docetaxel for this type of cancer. Some background PD-L1 is a protein that...
Read More
In a nutshell The study investigates measuring cellular CDK levels to predict the outcome of early stage-NSCLC patients. Some background Non small-cell lung cancer (NSCLC) is a common type of lung cancer that can be difficult to treat. Even early-stage NSCLC treated with surgery has a poor 5-year survival rate (65%) due...
Read More
